miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD

Chong He, Yan Shi, Ruijin Wu, Mingming Sun, Leilei Fang, Wei Wu, Changqin Liu, Maochun Tang, Zhong Li, Ping Wang, Yingzi Cong, Zhanju Liu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective MicroRNA (miR)-301a is known to be involved in the tumourigenesis and pathogenesis of several autoimmune diseases, but it remains unclear whether miR-301a is associated with the pathogenesis of IBD. Methods miR-301a expression was assessed in peripheral blood mononuclear cells (PBMC) and inflamed mucosa of patients with IBD by quantitative real-time-PCR. Peripheral blood CD4+ T cells were transduced with lentivirus-encoding pre-miR-301a (LV-miR-301a) or a reverse complementary sequence of miR-301a (LV-anti-miR-301a), and their differentiation and activation were investigated in vitro. Antisense miR-301a was administered into mice during trinitrobenzene sulphonic acid (TNBS)-induced colitis to determine its role in colitis. Results miR-301a expression was significantly upregulated in PBMC and inflamed mucosa of patients with IBD compared with healthy controls. Stimulation with tumour necrosis factor-α (TNF-α) significantly enhanced miR-301a expression in IBD CD4+ T cells, which was markedly reversed by anti-TNF-α mAb (Infliximab) treatment. Transduction of LV-miR-301a into CD4+ T cells from patients with IBD promoted the Th17 cell differentiation and TNF-α production compared with the cells with expression of LV-anti-miR-301a. SNIP1 as a functional target of miR-301a was reduced in miR-301a expression but increased in LV-anti-miR-301a expression. Knockdown of SNIP1 could enhance Th17 cell differentiation. Furthermore, intracolonical administration of antisense miR-301a in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A<sup>+</sup> cells and amounts of pro-inflammatory cytokines (eg, IL-17A, TNF-α) in inflamed colon. Conclusions Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. Blockade of miR-301a in vivo may serve as a novel therapeutic approach in the treatment of IBD.

Original languageEnglish (US)
JournalGut
DOIs
StateAccepted/In press - Sep 3 2015

Fingerprint

Interleukin-17
MicroRNAs
Tumor Necrosis Factor-alpha
Inflammation
Th17 Cells
Colitis
Trinitrobenzenes
Cell Differentiation
Blood Cells
Lentivirus
Mucous Membrane
Sulfonic Acids
T-Lymphocytes

ASJC Scopus subject areas

  • Gastroenterology

Cite this

miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. / He, Chong; Shi, Yan; Wu, Ruijin; Sun, Mingming; Fang, Leilei; Wu, Wei; Liu, Changqin; Tang, Maochun; Li, Zhong; Wang, Ping; Cong, Yingzi; Liu, Zhanju.

In: Gut, 03.09.2015.

Research output: Contribution to journalArticle

He, Chong ; Shi, Yan ; Wu, Ruijin ; Sun, Mingming ; Fang, Leilei ; Wu, Wei ; Liu, Changqin ; Tang, Maochun ; Li, Zhong ; Wang, Ping ; Cong, Yingzi ; Liu, Zhanju. / miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD. In: Gut. 2015.
@article{ae98fbe1a0b946c9ae882d240fac789d,
title = "miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD",
abstract = "Objective MicroRNA (miR)-301a is known to be involved in the tumourigenesis and pathogenesis of several autoimmune diseases, but it remains unclear whether miR-301a is associated with the pathogenesis of IBD. Methods miR-301a expression was assessed in peripheral blood mononuclear cells (PBMC) and inflamed mucosa of patients with IBD by quantitative real-time-PCR. Peripheral blood CD4+ T cells were transduced with lentivirus-encoding pre-miR-301a (LV-miR-301a) or a reverse complementary sequence of miR-301a (LV-anti-miR-301a), and their differentiation and activation were investigated in vitro. Antisense miR-301a was administered into mice during trinitrobenzene sulphonic acid (TNBS)-induced colitis to determine its role in colitis. Results miR-301a expression was significantly upregulated in PBMC and inflamed mucosa of patients with IBD compared with healthy controls. Stimulation with tumour necrosis factor-α (TNF-α) significantly enhanced miR-301a expression in IBD CD4+ T cells, which was markedly reversed by anti-TNF-α mAb (Infliximab) treatment. Transduction of LV-miR-301a into CD4+ T cells from patients with IBD promoted the Th17 cell differentiation and TNF-α production compared with the cells with expression of LV-anti-miR-301a. SNIP1 as a functional target of miR-301a was reduced in miR-301a expression but increased in LV-anti-miR-301a expression. Knockdown of SNIP1 could enhance Th17 cell differentiation. Furthermore, intracolonical administration of antisense miR-301a in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A+ cells and amounts of pro-inflammatory cytokines (eg, IL-17A, TNF-α) in inflamed colon. Conclusions Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. Blockade of miR-301a in vivo may serve as a novel therapeutic approach in the treatment of IBD.",
author = "Chong He and Yan Shi and Ruijin Wu and Mingming Sun and Leilei Fang and Wei Wu and Changqin Liu and Maochun Tang and Zhong Li and Ping Wang and Yingzi Cong and Zhanju Liu",
year = "2015",
month = "9",
day = "3",
doi = "10.1136/gutjnl-2015-309389",
language = "English (US)",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF-α in IBD

AU - He, Chong

AU - Shi, Yan

AU - Wu, Ruijin

AU - Sun, Mingming

AU - Fang, Leilei

AU - Wu, Wei

AU - Liu, Changqin

AU - Tang, Maochun

AU - Li, Zhong

AU - Wang, Ping

AU - Cong, Yingzi

AU - Liu, Zhanju

PY - 2015/9/3

Y1 - 2015/9/3

N2 - Objective MicroRNA (miR)-301a is known to be involved in the tumourigenesis and pathogenesis of several autoimmune diseases, but it remains unclear whether miR-301a is associated with the pathogenesis of IBD. Methods miR-301a expression was assessed in peripheral blood mononuclear cells (PBMC) and inflamed mucosa of patients with IBD by quantitative real-time-PCR. Peripheral blood CD4+ T cells were transduced with lentivirus-encoding pre-miR-301a (LV-miR-301a) or a reverse complementary sequence of miR-301a (LV-anti-miR-301a), and their differentiation and activation were investigated in vitro. Antisense miR-301a was administered into mice during trinitrobenzene sulphonic acid (TNBS)-induced colitis to determine its role in colitis. Results miR-301a expression was significantly upregulated in PBMC and inflamed mucosa of patients with IBD compared with healthy controls. Stimulation with tumour necrosis factor-α (TNF-α) significantly enhanced miR-301a expression in IBD CD4+ T cells, which was markedly reversed by anti-TNF-α mAb (Infliximab) treatment. Transduction of LV-miR-301a into CD4+ T cells from patients with IBD promoted the Th17 cell differentiation and TNF-α production compared with the cells with expression of LV-anti-miR-301a. SNIP1 as a functional target of miR-301a was reduced in miR-301a expression but increased in LV-anti-miR-301a expression. Knockdown of SNIP1 could enhance Th17 cell differentiation. Furthermore, intracolonical administration of antisense miR-301a in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A+ cells and amounts of pro-inflammatory cytokines (eg, IL-17A, TNF-α) in inflamed colon. Conclusions Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. Blockade of miR-301a in vivo may serve as a novel therapeutic approach in the treatment of IBD.

AB - Objective MicroRNA (miR)-301a is known to be involved in the tumourigenesis and pathogenesis of several autoimmune diseases, but it remains unclear whether miR-301a is associated with the pathogenesis of IBD. Methods miR-301a expression was assessed in peripheral blood mononuclear cells (PBMC) and inflamed mucosa of patients with IBD by quantitative real-time-PCR. Peripheral blood CD4+ T cells were transduced with lentivirus-encoding pre-miR-301a (LV-miR-301a) or a reverse complementary sequence of miR-301a (LV-anti-miR-301a), and their differentiation and activation were investigated in vitro. Antisense miR-301a was administered into mice during trinitrobenzene sulphonic acid (TNBS)-induced colitis to determine its role in colitis. Results miR-301a expression was significantly upregulated in PBMC and inflamed mucosa of patients with IBD compared with healthy controls. Stimulation with tumour necrosis factor-α (TNF-α) significantly enhanced miR-301a expression in IBD CD4+ T cells, which was markedly reversed by anti-TNF-α mAb (Infliximab) treatment. Transduction of LV-miR-301a into CD4+ T cells from patients with IBD promoted the Th17 cell differentiation and TNF-α production compared with the cells with expression of LV-anti-miR-301a. SNIP1 as a functional target of miR-301a was reduced in miR-301a expression but increased in LV-anti-miR-301a expression. Knockdown of SNIP1 could enhance Th17 cell differentiation. Furthermore, intracolonical administration of antisense miR-301a in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A+ cells and amounts of pro-inflammatory cytokines (eg, IL-17A, TNF-α) in inflamed colon. Conclusions Our data reveal a novel mechanism in which the elevated miR-301a in PBMC and inflamed mucosa of IBD promotes Th17 cell differentiation through downregulation of SNIP1. Blockade of miR-301a in vivo may serve as a novel therapeutic approach in the treatment of IBD.

UR - http://www.scopus.com/inward/record.url?scp=84940919418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940919418&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2015-309389

DO - 10.1136/gutjnl-2015-309389

M3 - Article

C2 - 26338824

AN - SCOPUS:84940919418

JO - Gut

JF - Gut

SN - 0017-5749

ER -